• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Forma Therapeutics Holdings, Inc.

    Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics Announces Appointment of New Executive Team Members
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics to Present at the Jefferies Healthcare Conference
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics’ Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics’ Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics’ FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics to Participate in Upcoming Investor Conferences
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics to Participate in Upcoming Investor Conferences
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021
    From Forma Therapeutics Holdings, Inc.
    Via Business Wire
    Tickers FMTX
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.